InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Submission of Clinical Trial Protocol for Unbuzzd(TM) Study
FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has submitted a clinical trial protocol to assess the safety and efficacy of Unbuzzd(TM) in healthy volunteers. The clinical trial protocol for the METAL-2 trial will be reviewed by the U.S. institutional review board. After receiving approval,…